SCHEMBL4237483

SCHEMBL4237483

Cc1ccc(C(C)(C)C)cc1Oc1nc(C(=O)O)co1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.39
KLKB1 P03952 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
CYP2C9 P11712 2/20 0.34
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 2/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33
RXRB P28702 2/20 0.32
RXRA P19793 1/20 0.32
RXRG P48443 1/20 0.32
TDP1 Q9NUW8 2/20 0.32
TSHR P16473 2/20 0.32
TTR P02766 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C8 P10632 1/20 0.32
CHRM1 P11229 1/20 0.32
ADRA1A P35348 1/20 0.32
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4233103 0.86 NLRP3 (0.40) NLRP3KLKB1CYP2C9LMNASMN1; SMN2
SCHEMBL2871936 0.80 P2RX3 (0.42) KLKB1LMNASMN1; SMN2HTTKMT2A
SCHEMBL1660892 0.80 BCHE (0.42) NLRP3
SCHEMBL1661912 0.79 KLKB1 (0.42) KLKB1CYP2C9LMNAHTTCYP2C19
SCHEMBL4231566 0.78 NLRP3 (0.37) NLRP3KLKB1HTTTSHR
SCHEMBL4238578 0.77 NLRP3 (0.41) NLRP3KLKB1CYP2C9HTTCYP2C19
SCHEMBL4242158 0.76 GNRHR (0.36) NLRP3KLKB1CYP2C9HTTTSHR
SCHEMBL4233510 0.75 ALDH1A1 (0.39) MRGPRX4CYP2C9LMNASMN1; SMN2CYP2C19
SCHEMBL13743552 0.74 GNRHR (0.37) NLRP3KLKB1CYP2C9HTTCYP2C19
SCHEMBL4236125 0.74 GNRHR (0.37) NLRP3KLKB1CYP2C9HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209522-A1 Heterocyclic Non-Peptide GNRH Antagonists TAKEDA CAMBRIDGE LIMITED (GB) 2009-08-20 US disclosed
EP-1896465-A1 HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS Takeda Cambridge Limited (GB) 2008-03-12 EP disclosed
WO-2007000582-A1 HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS TAKEDA CAMBRIDGE LIMITED (GB) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209522-A1 Heterocyclic Non-Peptide GNRH Antagonists GNRHR, GHRHR, FSHR NLRP3 3350/4885KLKB1 2239/4885MRGPRX4 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.